PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Nov 3, 2015
SOUTH PLAINFIELD, N.J., Nov. 3, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced  that management will present a company update at the following conferences: Credit Suisse 24th Annual Healthcare Conference, on Wednesday, November 11th at 8:30 a.m. MT at The Phoenician in Scottsdale, AZ Stifel Nicolaus Health...
Oct 29, 2015
SOUTH PLAINFIELD, N.J., Oct. 29, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the expansion of its Strategies to Realize Innovation, Vision and Empowerment (STRIVE) Awards program to provide funding to nonprofit organizations serving the cystic fibrosis (CF) community by developing unique programs that will raise aware...
Oct 27, 2015
SOUTH PLAINFIELD, N.J., Oct. 27, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2015 financial results and provide an update on the Company's business, outlook and clinical programs. The call will take place on Monday, November 9, 2015 at 4:...
Oct 15, 2015
SOUTH PLAINFIELD, N.J., Oct. 15, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced results from the Phase 3, double-blind, placebo-controlled, 48-week ACT DMD trial of Translarna™ (ataluren), an oral, first-in-class, protein restoration therapy for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD)...
Oct 4, 2015
BRIGHTON, United Kingdom, Oct. 4, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that clinical data from the company's joint development program with Roche and the SMA Foundation in spinal muscular atrophy (SMA) were presented at the 20th International Congress of the World Muscle Society (WMS) in Brighton, U.K. Results...
Oct 2, 2015
SOUTH PLAINFIELD, N.J., Oct. 2, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on October 2, 2015 it approved non-statutory stock options to purchase an aggregate of 58,300 shares of its common stock to 13 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new...
Sep 30, 2015
SOUTH PLAINFIELD, N.J., Sept. 30, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the European Medicines Agency (EMA) has validated the submission of a variation for a new indication for Translarna™ (ataluren) for the treatment of nonsense mutation cystic fibrosis (nmCF) for patients not taking chronic inhaled...
Sep 4, 2015
SOUTH PLAINFIELD, N.J., Sept. 4, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce five recipients of its first-ever global awards program, the STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment), designed to aid nonprofit organizations that are committed to serving the Duchenne muscular dystroph...
Aug 21, 2015
SOUTH PLAINFIELD, N.J., Aug. 21, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on August 20, 2015 it approved non-statutory stock options to purchase an aggregate of 166,200 shares of its common stock to 35 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our n...
Aug 14, 2015
SOUTH PLAINFIELD, N.J., Aug. 14, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the closing of its previously announced private offering of $150 million in aggregate principal amount of its convertible senior notes due 2022 (the "Notes"), including the full exercise by the initial purchasers of an option to purchase an a...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue